PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy.
Reis Costa D, Winge-Main AK, Skog A, Tsuruda KM, Robsahm TE, Kulle Andreassen B(2024) From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway Acta Oncol, 63, 965-973 DOI 10.2340/1651-226X.2024.41266, PubMed 39690735
Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD(2024) Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma Front Immunol, 15, 1480183 DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
Safont MM, Leitch C, Popa M, Gjerstad ME, Caulier B, Inderberg EM, Wälchli S, Gelebart P, Cormack EM(2024) Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy STAR Protoc, 5(4), 103522(in press) DOI 10.1016/j.xpro.2024.103522, PubMed 39673705
